We are delighted to announce that funds advised by Yana Investment Partners have successfully exited their investment in Essential Pharma through a sale of the business to a EUR 600m continuation vehicle.
Since acquiring Essential Pharma in 2019, our investment partner Gyrus has worked closely with the company’s leadership team to transform the company into a global specialty pharma group, addressing critical patient needs across niche and rare disease therapeutic areas.